KRAS
A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.
Coverage of KRAS is holding steady : 10 signals on the latest tracked day, down 47% from its three-week baseline of 19, across 3 domains (unchanged from a week ago). That makes it the #3 most-covered of the 274 concerns we track.
What’s changed
5 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- The Long, Remarkable History of KRAS and Pancreatic Cancer: From Gene Discovery to Successful Therapeutic Targeting. · Mod Pathol · 2026-08-05
- SIL204 treatment may help immune system attack KRAS-driven tumors, research finds - exclusive - The Jerusalem Post · KRAS Mutation Research (Google News) · 2026-08-05
- M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors - Nature · KRAS Mutation Research (Google News) · 2026-08-05
- FDA grants breakthrough status to Lilly’s KRAS G12C inhibitor for pancreatic cancer - gxpnews.net · KRAS Mutation Research (Google News) · 2026-08-05
- Dr Riess on the Differences Between KRAS(ON), KRAS(OFF), and KRAS(ON/OFF) Inhibitors in Lung Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-08-05
What the reporting says
It shows up alongside Colorectal Cancer (94), Pancreatic Cancer (56), Immunotherapy (18), Egfr (17), ctDNA (14), Eli Lilly (11), FDA (16).
Two steps out: AI (through Colorectal Cancer, 57 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 54 shared stories on the weaker link); China (through Colorectal Cancer, 33 shared stories on the weaker link); Nuclear (through Colorectal Cancer, 21 shared stories on the weaker link).
Tracked since Mar 11, with coverage on 117 separate days — concentrated in Oncology and Pubmed Targeted.